Advanced Prostate Cancer Clinical Challenge
Reviewed by: HU Medical Review Board | Last reviewed: October 2026 | Last updated: October 2026
Imaging criteria, clinical signs of aggressive disease, and supportive care during chemotherapy all shape decisions in metastatic castration-resistant prostate cancer (mCRPC). These 5 questions test current guidance and trial evidence in each area.
Clinical Challenge
Under the Society of Nuclear Medicine and Molecular Imaging (SNMMI) appropriate use criteria, which scenario is rated "appropriate" for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)?
Clinical Challenge
In the prospective trial that defined clinical criteria for aggressive variant ("anaplastic") castration-resistant prostate cancer, which feature qualified a patient?
Clinical Challenge
A 77-year-old man with mCRPC and prior pelvic radiation is starting full-dose docetaxel, a regimen with an intermediate (10 to 20 percent) risk of febrile neutropenia. What do National Comprehensive Cancer Network (NCCN) guidelines advise about primary granulocyte colony-stimulating factor (G-CSF) prophylaxis?
Clinical Challenge
In the VISION trial of radioligand therapy, how was a metastatic lesion defined as PSMA-positive on gallium-68 PSMA-11 PET?
Clinical Challenge
What is the recommended starting dose of cabazitaxel in mCRPC under current labeling?